TYRA
Tyra Biosciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-44/100
Last price
20.05
▼ 0.88 (4.20%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
18.50
Prev close
20.93
Day high
20.99
Day low
19.60
Volume
763.38K
Market cap
$1.39B
P/E (TTM)
—
52W range
13.17 – 40.65
Day trading desk
Gap from prior close
-11.61%
Prior close 20.93
VWAP
20.22
-0.82% from price
Relative volume
1.62×
Unusually busy
Session range
15.30%
18.50 – 21.33
Position in range
55%
Mid range
ATR (14D)
1.29
6.43% of price
Prior day high
21.03
PDH
Prior day low
19.94
PDL
Bid / ask spread
—
Quote not published
Session volume
1.39M
Avg 859.13K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.92%
-9.9%
1M
-29.35%
-30.5%
3M
-37.86%
-42.4%
6M
-46.36%
-64.5%
YTD
-23.01%
-37.3%
1Y
+48.17%
+31.8%
3Y
+46.99%
-35.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TYRA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.45M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 9, 26 | VERJEE REHAN Director |
BUY | 971 | $20.00K | Direct |
| May 5, 26 | HARRIS TODD JAMES Chief Executive Officer |
STOCK | 79.00K | $0 | Direct |
| May 5, 26 | FUHRMAN ALAN CPA Chief Financial Officer |
STOCK | 20.00K | $0 | Direct |
| May 5, 26 | ASHAR BHAVESH Chief Operating Officer |
STOCK | 15.01K | $0 | Direct |
| May 5, 26 | WARNER DOUGLAS J Officer |
STOCK | 25.00K | $0 | Direct |
| May 5, 26 | RUEB YULIYA Officer |
STOCK | 8.33K | $0 | Direct |
| Mar 26, 26 | KAPLAN GILLA Director |
CONVERSION | 67.47K | $151.80K | Direct |
| Mar 25, 26 | KAPLAN GILLA Director |
SELL | 14.29K | $528.51K | Direct |
| Mar 13, 26 | HARRIS TODD JAMES Chief Executive Officer |
STOCK | 1.46K | $52.99K | Direct |
| Mar 13, 26 | FUHRMAN ALAN CPA Chief Financial Officer |
STOCK | 1.38K | $49.84K | Direct |
| Feb 12, 26 | BENSEN DANIEL Officer |
SELL | 8.00K | $262.96K | Direct |
| Jan 12, 26 | BENSEN DANIEL Officer |
SELL | 8.00K | $228.19K | Direct |
| Dec 19, 25 | MORE ROBERT J Director |
SELL | 10.00K | $250.00K | Indirect |
| Dec 12, 25 | BENSEN DANIEL Officer |
SELL | 8.00K | $181.16K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ASHAR BHAVESH |
Chief Operating Officer | 15.01K | Stock Award(Grant) |
BENSEN DANIEL |
Officer | 146.98K | Sale |
FUHRMAN ALAN CPA |
Chief Financial Officer | 36.16K | Stock Award(Grant) |
HARRIS TODD JAMES |
Chief Executive Officer | 1.44M | Stock Award(Grant) |
KAPLAN GILLA |
Director | 28.23K | Conversion of Exercise of derivative security |
KJELLSON NINA S |
Director | — | Sale |
MORE ROBERT J |
Director | — | Sale |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RUEB YULIYA |
Officer | 43.35K | Stock Award(Grant) |
WARNER DOUGLAS J |
Officer | 25.00K | Stock Award(Grant) |
Fundamentals
Market cap$1.39B
Enterprise value$859.50M
Revenue (TTM)—
Gross profit—
EBITDA$-159.92M
Net income$-148.56M
EPS (TTM)$-2.32
Free cash flow$-63.07M
Total cash$353.94M
Total debt$5.58M
Book value / share$5.93
Shares outstanding68.76M
Float34.65M
Short % of float23.82%
Dividend yield0.00%
Beta (5Y)0.75
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.31
PEG ratio—
Price / sales—
Price / book3.41
EV / revenue—
EV / EBITDA-5.37
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-45.31%
Return on assets-28.46%
Debt / equity1.58
Current ratio14.91
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $102.93M | $80.08M | $62.52M | $43.01M | +28.5% |
| Selling, general & admin | $29.83M | $24.10M | $17.43M | $15.92M | +23.8% |
| Total operating expense | $132.76M | $104.18M | $79.94M | $58.93M | +27.4% |
| Operating income | -$132.76M | -$104.18M | -$79.94M | -$58.93M | -27.4% |
| Net interest income | $12.81M | $17.70M | $10.81M | $3.65M | -27.6% |
| Pre-tax income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -38.7% |
| Net income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -38.7% |
| Net income to common | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -38.7% |
| Basic EPS | -2.01 | -1.51 | -1.62 | -1.32 | -33.1% |
| Diluted EPS | -2.01 | -1.51 | -1.62 | -1.32 | -33.1% |
| EBIT | -$132.76M | -$104.18M | -$79.94M | -$58.93M | -27.4% |
| EBITDA | -$132.22M | -$103.66M | -$79.59M | -$58.63M | -27.6% |
| Basic shares | 59.60M | 57.22M | 42.70M | 41.88M | +4.2% |
| Diluted shares | 59.60M | 57.22M | 42.70M | 41.88M | +4.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $77.39M | $91.97M | $58.01M | $251.21M | -15.9% |
| Cash & short-term investments | $256.00M | $341.44M | $203.47M | $251.21M | -25.0% |
| Total current assets | $265.45M | $347.46M | $211.67M | $257.29M | -23.6% |
| Property, plant & equipment | $6.89M | $7.72M | $8.15M | $3.54M | -10.8% |
| Total assets | $282.61M | $363.56M | $225.86M | $266.18M | -22.3% |
| Total current liabilities | $18.09M | $14.59M | $15.33M | $5.70M | +24.0% |
| Total debt | $5.81M | $6.22M | $6.50M | $2.62M | -6.6% |
| Total liabilities | $23.43M | $20.41M | $21.59M | $8.35M | +14.8% |
| Retained earnings | -$371.26M | -$251.31M | -$164.83M | -$95.70M | -47.7% |
| Shareholder equity | $259.18M | $343.15M | $204.26M | $257.83M | -24.5% |
| Working capital | $247.36M | $332.87M | $196.34M | $251.59M | -25.7% |
| Net tangible assets | $259.18M | $343.15M | $204.26M | $257.83M | -24.5% |
| Shares issued | 53.71M | 50.75M | 43.02M | 42.35M | +5.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -38.7% |
| Depreciation & amortisation | $546.00K | $519.00K | $357.00K | $296.00K | +5.2% |
| Stock-based compensation | $28.01M | $22.80M | $13.53M | $10.59M | +22.8% |
| Change in working capital | -$1.63M | -$729.00K | $6.36M | -$5.85M | -123.3% |
| Operating cash flow | -$95.14M | -$69.77M | -$50.14M | -$50.28M | -36.4% |
| Capital expenditure | -$141.00K | -$664.00K | -$770.00K | -$559.00K | +78.8% |
| Investing cash flow | $72.46M | -$98.40M | -$144.60M | -$559.00K | +173.6% |
| Share buybacks | $0 | -$420.00K | $0 | — | +100.0% |
| Financing cash flow | $8.10M | $202.14M | $1.54M | $632.00K | -96.0% |
| Free cash flow | -$95.28M | -$70.44M | -$50.91M | -$50.84M | -35.3% |
| End cash position | $78.39M | $92.97M | $59.01M | $252.21M | -15.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $39.20M | $33.47M | $28.19M | $25.47M | $24.31M | +17.1% |
| Selling, general & admin | $9.81M | $8.53M | $8.33M | $7.47M | $7.14M | +15.0% |
| Total operating expense | $49.00M | $42.00M | $36.52M | $32.94M | $31.45M | +16.7% |
| Operating income | -$49.00M | -$42.00M | -$36.52M | -$32.94M | -$31.45M | -16.7% |
| Net interest income | $3.44M | $2.69M | $2.68M | $3.08M | $3.35M | +27.9% |
| Pre-tax income | -$45.56M | -$39.30M | -$33.83M | -$29.87M | -$28.10M | -15.9% |
| Net income | -$45.56M | -$39.30M | -$33.83M | -$29.87M | -$28.10M | -15.9% |
| Net income to common | -$45.56M | -$39.30M | -$33.83M | -$29.87M | -$28.10M | -15.9% |
| Basic EPS | -0.69 | -0.64 | -0.57 | -0.50 | -0.47 | -7.8% |
| Diluted EPS | -0.69 | -0.64 | -0.57 | -0.50 | -0.47 | -7.8% |
| EBIT | -$49.00M | -$42.00M | -$36.52M | -$32.94M | -$31.45M | -16.7% |
| EBITDA | -$48.87M | -$41.86M | -$36.38M | -$32.81M | -$31.31M | -16.7% |
| Basic shares | 65.99M | 61.75M | 59.83M | 59.67M | 59.55M | +6.9% |
| Diluted shares | 65.99M | 61.75M | 59.83M | 59.67M | 59.55M | +6.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $73.83M | $84.95M | $77.39M | $61.95M | $98.49M | -13.1% |
| Cash & short-term investments | $353.94M | $383.47M | $256.00M | $274.92M | $296.27M | -7.7% |
| Total current assets | $366.97M | $394.61M | $265.45M | $281.22M | $302.15M | -7.0% |
| Property, plant & equipment | $6.48M | $6.66M | $6.89M | $7.04M | $7.24M | -2.6% |
| Total assets | $383.36M | $412.04M | $282.61M | $301.85M | $321.50M | -7.0% |
| Total current liabilities | $24.62M | $19.26M | $18.09M | $15.88M | $13.77M | +27.9% |
| Total debt | $5.58M | $5.70M | $5.81M | $5.92M | $6.02M | -2.0% |
| Total liabilities | $29.70M | $24.46M | $23.43M | $21.34M | $19.35M | +21.4% |
| Retained earnings | -$456.12M | -$410.56M | -$371.26M | -$337.42M | -$307.56M | -11.1% |
| Shareholder equity | $353.66M | $387.57M | $259.18M | $280.51M | $302.15M | -8.7% |
| Working capital | $342.35M | $375.36M | $247.36M | $265.34M | $288.38M | -8.8% |
| Net tangible assets | $353.66M | $387.57M | $259.18M | $280.51M | $302.15M | -8.7% |
| Shares issued | 59.66M | 59.47M | 53.71M | 53.32M | 53.23M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$45.56M | -$39.30M | -$33.83M | -$29.87M | -$28.10M | — | -15.9% |
| Depreciation & amortisation | $138.00K | $138.00K | $132.00K | $131.00K | $140.00K | — | 0.0% |
| Stock-based compensation | $10.23M | $7.85M | $7.63M | $7.58M | $6.38M | — | +30.4% |
| Change in working capital | $4.32M | -$1.23M | $2.58M | $199.00K | -$1.39M | — | +452.1% |
| Operating cash flow | -$31.08M | -$32.57M | -$23.62M | -$22.38M | -$23.68M | — | +4.6% |
| Capital expenditure | -$66.00K | -$88.00K | -$57.00K | -$39.00K | -$31.00K | — | +25.0% |
| Investing cash flow | $17.85M | -$120.24M | $34.38M | -$14.81M | $20.87M | — | +114.8% |
| Share buybacks | — | — | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $2.10M | $160.38M | $4.68M | $647.00K | $583.00K | — | -98.7% |
| Free cash flow | -$31.14M | -$32.66M | -$23.68M | -$22.42M | -$23.71M | — | +4.6% |
| End cash position | $74.83M | $85.95M | $78.39M | $62.95M | $99.49M | — | -12.9% |
Options analytics
Put / call volume
28.19
Put-heavy session
Put / call open interest
23.51
Positioning, not flow
Max pain
22.50
+11.2% from spot
ATM implied vol
175.8%
Nearest strike to spot
Skew (10% OTM)
+204.3%
Puts bid over calls
Call volume
89
Contracts, this expiry
Put volume
2.51K
Contracts, this expiry
Heaviest call OI
27.50
49 contracts
Heaviest put OI
22.50
4.01K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.64 | -0.69 | -7.0% |
| Mar 2026 | -0.59 | -0.64 | -8.6% |
| Dec 2025 | -0.53 | -0.57 | -8.5% |
| Sep 2025 | -0.51 | -0.50 | +2.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.67 | 14 | $0 | 0.0% |
| Next quarter | -0.67 | 14 | $0 | 0.0% |
| Current year | -2.64 | 14 | $0 | 0.0% |
| Next year | -2.77 | 14 | $0 | 0.0% |
Analyst targets & ownership
Mean target$47.45
High target$59.00
Low target$29.00
Implied upside136.68%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy2 / 12
Hold1
Sell / Strong sell0 / 0
Held by insiders2.43%
Held by institutions108.25%
Institutions holding238
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
21.53
-6.88% from price
SMA 20
22.96
-11.83% from price
SMA 50
25.47
-20.53% from price
SMA 100
28.21
-28.92% from price
SMA 200
30.49
-33.61% from price
EMA 12
21.91
-8.50% from price
EMA 26
23.35
-14.13% from price
EMA 50
25.12
-20.18% from price
RSI (14)
35.5
Neutral
MACD (12,26,9)
-1.44
Hist -0.22
ATR (14)
1.29
6.37% of price
Realised vol 30D
96.4%
Annualised
Bollinger upper
26.60
20, 2σ
Bollinger lower
19.31
20, 2σ
50 / 200 cross
Death
25.47 vs 30.49
Trend bias
Below 200
-33.61%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.54
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
96.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-48.9%
Peak to trough
Max drawdown 5Y
-83.2%
Peak to trough
ATR 14
1.29
6.37% of price
Beta (reported)
0.75
5Y monthly, from filing
Short interest
Shares short
9.88M
Prior 9.69M
Change vs prior
+1.9%
Shorts adding
% of float
23.82%
Heavily shorted
% of shares out
14.37%
Against total outstanding
Days to cover
9.5
Crowded exit
Float
34.65M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Sep 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 10, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 17, 26 | Jones Trading | INITIATED | — | Buy |
| Jun 10, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| May 19, 26 | Wolfe Research | INITIATED | — | Peer Perform |
| May 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 15, 26 | Guggenheim | INITIATED | — | Buy |
| Apr 6, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Mar 20, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-15
Corporate Changes & Voting Matters
8-K · 2026-09-09
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-02
Periodic Financial Reports
10-Q · 2026-05-13
Proxy Statements
DEFA14A · 2026-04-17
Corporate Changes & Voting Matters
8-K · 2026-04-02
Corporate Changes & Voting Matters
8-K · 2026-03-04
Headlines
Raymond James Updates Healthcare Top Picks for October
Investing.com · 5d ago
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?
Insider Monkey · 20d ago
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets
Simply Wall St. · 21d ago
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PR Newswire · 23d ago
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
Investor's Business Daily · 27d ago
Tyra disappoints investors with bladder cancer data
BioPharma Dive · 28d ago
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Barrons.com · 28d ago
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
InvestorsHub · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.